NEWS
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics (NASDAQ: PRLD) announced promising initial clinical data for PRT3789, its first-in-class SMARCA2 degrader, in a Phase 1 trial. The drug showed encouraging anti-tumor activityin patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. Key findings include:
- 3 confirmed partial responses observed
- 7 out of 26 evaluable NSCLC or esophageal patients showed tumor shrinkage
- Generally well-tolerated safety profile with no dose-limiting toxicities
- Dose escalation continuing to 9th cohort (500mg once weekly)
The company plans to confirm the biologically active dose for PRT3789 monotherapy by year-end and advance combination studies with docetaxel. These results represent initial proof of concept for selective SMARCA2 degradation in certain SMARCA4 mutated cancers.
- 3 confirmed partial responses observed
- 7 out of 26 evaluable NSCLC or esophageal patients showed tumor shrinkage
- Generally well-tolerated safety profile with no dose-limiting toxicities
- Dose escalation continuing to 9th cohort (500mg once weekly)
The company plans to confirm the biologically active dose for PRT3789 monotherapy by year-end and advance combination studies with docetaxel. These results represent initial proof of concept for selective SMARCA2 degradation in certain SMARCA4 mutated cancers.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1842Followers
99Following
15KVisitors
Follow